CN106913583A - The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents - Google Patents
The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents Download PDFInfo
- Publication number
- CN106913583A CN106913583A CN201710262634.8A CN201710262634A CN106913583A CN 106913583 A CN106913583 A CN 106913583A CN 201710262634 A CN201710262634 A CN 201710262634A CN 106913583 A CN106913583 A CN 106913583A
- Authority
- CN
- China
- Prior art keywords
- excretion body
- preparation
- stem cell
- mesenchymal stem
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to biomedicine field, and in particular to a kind of preparation method and application of human mesenchymal stem cell source excretion body biologically active agents.Method is as follows：Weigh the 400mg of shitosan 50, it is dissolved in the spirit of vinegar of 25 200mL, obtains chitosan solution, weighs the 10mg of human mesenchymal stem cell source excretion body freeze-dried powder 1, the 20mg of glucose GAG 2, the 20mg of hyaluronic acid 2, it is dissolved in 10 100mL glycerine, obtains excretion liquid solution；Excretion liquid solution is added drop-wise in chitosan solution, the chitosan nano particle suspension of excretion body is obtained；Suspension is carried out into centrifugal treating, sediment is collected, washed and dried process, obtain cosmetic formulation.Solve the problems, such as the skin aging of people.The problem for frequently using is overcome, the adverse reaction of cosmetic formulation is advantageously reduced, the valid density of active component can be in a long time maintained, greatest treatment efficacy is reached with minimum dose.
Description
Technical field
The invention belongs to biomedicine field, and in particular to a kind of human mesenchymal stem cell source excretion body biologically active agents
Preparation method and application.
Background technology
It is well known that normal cell, and tumour cell, it is required for carrying out cell-cell communication by cell secretion vector,
To maintain physiological status and activity.Wherein, excretion body is a kind of important cell-cell communication carrier, can be by the thin of all kinds
Born of the same parents produce, and have been found in the middle of each pseudo body fluid, including blood, lymph, urine and milk.The research knot of nearly 30 years
Fruit shows that excretion body carries abundant cell source material, including liposome, protein, mRNA, non-coding RNA, or even DNA
Fragment.The not simple cellular elements rubbish of excretion body, they can be absorbed by other cells.Therefore, excretion body can be
Intercellular trafficking biological information, so as to play key player in cell physiological function aspects.Especially, excretion body is also assisted in
The progression of some diseases, including tumour and nerve degenerative diseases.As the research to excretion body deepens continuously, people couple
The extremely complex and abstruse mechanism of action in terms of excretion body is in human health and disease, have it is very deep be appreciated and understood by,
And then start to notice excretion body for the clinical practice in terms of disease prevention and cure, body-care, especially anti-aging and cosmetic applications.
Excretion body participates in the maintenance stage in human body normal physiological activity, the maintenance of such as stem cell, and tissue repair.
Research shows, in the development and atomization of human body, excretion body plays a part of morphogenetic factor transfer vector.Outside these
Secrete body to be discharged by donorcells first, then spread around adjacent tissue, form different concentration bands, finally complete iuntercellular
The process of communication.It is of special importance that existing multinomial research finds, the excretion body of stem cell release for wounded tissue, especially
It is the regeneration and recovery of aging skin, plays very crucial effect.
In the prior art, the anti-aging effects of most of cosmetic formulations are undesirable, and cosmetic result hold time it is shorter,
Needs are commonly used, and human cost and time cost are higher.
The content of the invention
Therefore, the technical problems to be solved by the invention are to overcome existing cosmetic formulation anti-aging effects unobvious,
Technical bottleneck of the excretion body as raw material seldom is used, so as to propose a kind of sustained release beauty of human mesenchymal stem cell source excretion body
The preparation method of preparation.
In order to solve the above technical problems, the invention discloses a kind of mescenchymal stem cell source excretion body biologically active agents
Preparation method, the preparation method of the preparation is as follows：
1) shitosan 50-400mg is weighed, is dissolved in the spirit of vinegar of 25-200mL, obtain chitosan solution；
2) human mesenchymal stem cell source excretion body freeze-dried powder 1-10mg, glucose GAG 2-20mg, hyalomitome are weighed
Sour 2-20mg, is dissolved in 10-100mL glycerine, obtains excretion liquid solution；
3) described excretion liquid solution is added drop-wise in the chitosan solution, obtains the chitosan nano particle of excretion body
Suspension；
5) suspension is carried out into centrifugal treating, collects sediment, be washed out and dried process, obtained outside the source
Secrete body sustained release cosmetic formulation.
Preferably, the shitosan is 200mg, and spirit of vinegar is 100mL, and human mesenchymal stem cell source excretion body freeze-dried powder is
5mg, glucose GAG are 10mg, hyaluronic acid is 10mg, and glycerine is 50mL.
Preferably, the adventitia of the excretion body is phophoslipid bilayer structure, and micro-RNA, institute are contained in portion in the excretion body
State at least one in mRNA, DNA and nucleic acid of excretion body source cell.
Preferably, the acquisition methods step of the excretion body is as follows：
A) human mesenchymal stem cell is cultivated, cultivation stage added in cell culture medium interferon, EPO and
PDGF-BB；
B) stem cell after culture is pre-processed；
C) the human umbilical cord mesenchymal stem cells source excretion body is extracted in the supernatant of culture medium after the pre-treatment.
5th, preparation as claimed in claim 4, it is characterised in that the step 1) in, the spirit of vinegar concentration is
0.5%.
Preferably, the step 4) in, the speed of the centrifugal treating is 10000r/min, and the time is 30 minutes；It is described
Step 3) reaction time be 30 minutes；The step 4) in, the number of times of the washing is 3 times.
Preferably, the pretreatment is concretely comprised the following steps：
1) people's passage MSC is carried out into serum free suspension culture, and it is 1.0 × 10 to adjust cell concentration6/ml；
2) according to 106The big culture dish inoculations of/150mm, cultivate to cell fusion degree to 70-80%, and incubation time is 2-3
My god；
3) liquid in culture dish is absorbed, and culture dish is washed with alpha-MEM fluid nutrient medium；
4) alpha-MEM of 20ml is added again in 150mm culture dishes；
5) recombinant human interferon alpha 2, PDGF-BB and EPO are sequentially added；
7) at 37 DEG C, 5% CO2Under the conditions of cultivate 96 hours, collection obtain MSC nutrient solutions.
Preferably, the concentration of interferon is for 10U/ml~600U/ml, the concentration of PDGF-BB in the MSC nutrient solutions
The concentration of 2ng/ml~60ng/ml, EPO is 0.1IU/ml~5IU/ml.
Preferably, the step 2) pretreatment be specially：
1) supernatant of the MSC nutrient solutions is taken, centrifugal treating is carried out, cell fragment is removed；
2) and then by the treatment of supernatant membrane filtration, apoptotic body is removed, obtains pretreated supernatant.
It is more highly preferred to, the step 3) it is specially：
1) product of trying to please is the centrifuge tube of 5 parts by volume, adds the excretion body separation agent of 1 parts by volume；
2) add 4 parts by volume by pretreated supernatant, fully mix；
3) after stewing process, then centrifugal treating twice is carried out, obtains the excretion body.
The invention also discloses application of the preparation method described in any one in biological beauty preparation preparation field.
Above-mentioned technical proposal of the invention has advantages below compared to existing technology：The present invention is by human mesenchymal stem cell source
Excretion body is prepared for a kind of sustained release cosmetic formulation for having a positive effect as active component, can to a certain extent solve people
Skin aging problem.Skin is imported by methods such as laser, ultrasound, machineries, the skin aging of people is solved the problems, such as.Can be
The valid density of active component is maintained in long period, greatest treatment efficacy is reached with minimum dose, so as to save the time of user
And cost；With great market prospects and economic worth.
Specific embodiment
Embodiment
Embodiment 1, with Preparation Method, is comprised the following steps that present embodiment discloses a kind of cosmetic formulation：
1) shitosan 200mg is weighed, is dissolved in the spirit of vinegar of 100mL 0.5%, obtain chitosan solution.
2) human mesenchymal stem cell source excretion body freeze-dried powder 5mg, glucose GAG 10mg, hyaluronic acid are weighed
10mg, is dissolved in 50mL glycerine, obtains excretion liquid solution.
3) under continuous stirring, excretion liquid solution is slowly dropped in chitosan solution, is reacted 30 minutes, obtain final product excretion
The chitosan nano particle suspension of body.
4) suspension was collected into sediment, and washed with water for injection in 4 times high speed centrifugations (10000r/min) 30 minutes
3 times, human mesenchymal stem cell source excretion body sustained release cosmetic formulation is obtained final product after drying.
Method for preparing freeze-dried powder of the embodiment 2 present embodiment discloses excretion body described in embodiment 1
Excretion body is taken, mannitol (1%~15%) is added, mixed, filtered (0.22 μm), packing, then it is positioned over ultralow temperature
Refrigerator (- 80 DEG C) 10h.Then, (- 50 DEG C, 24h) are freezed under the vacuum of 10Pa, human mesenchymal stem cell source is obtained
Excretion body freeze-dried powder.
Preparation method of the embodiment 3 present embodiment discloses excretion body described in embodiment 2
A. the culture of people MSC and preprocessing process：
1. material and reagent
1) MSC in people's umbilical cord, placenta, marrow, fat or other sources, passage number is within 6 generations.
2) people MSC serum free mediums
3)alpha-MEM
4) recombinant human interferon alpha 2
5) recombinant human epo
6) rhPDGF-BB-BB
7) culture dish (diameter 150mm)
8) other consumptive materials
B. the incubation of cell
1) will be counted after people's passage MSC digestion, suspended using MSC Serum-free complete mediums, adjustment cell concentration is 1.0
×106/ml。
2) according to 106The big culture dish inoculations of/150mm, culture to cell fusion degree to 70-80%.Generally require 2-3 days.
3) liquid in culture dish is absorbed, and culture dish is washed with alpha-MEM fluid nutrient medium.
4) alpha-MEM 20ml/150mm culture dishes are added.
5) recombinant human interferon alpha 2, PDGF-BB are firstly added, in 37 DEG C, 5% CO2Under the conditions of cultivate 24 hours；Then,
EPO is added, in 37 DEG C, 5% CO2Under the conditions of cultivate 72 hours.
Recombinant human interferon alpha 2 (final concentration of 10U/ml~600U/ml), PDGF-BB (2ng/ml~60ng/ml) and EPO
(0.1IU/ml~5IU/ml).
7) 37 DEG C, cultivated 96 hours under the conditions of 5%CO2.
8) collecting supernatant carries out following treatment.Such as can not in time process, supernatant is placed in -80 DEG C of preservations.
C. the pretreatment of people MSC culture supernatants
1. material and reagent
1) consumptive material such as centrifuge tube.
2) aperture is 1 μm, 0.45 μm and 0.22 μm of filter.
1) 50ml centrifuge tubes are taken, excretion body separation agent 10ml is added.Or 250ml centrifuge tubes are taken, add excretion body reagent
50ml。
2) treated cells and supernatant 40ml is added, is fully mixed.Or add culture supernatant 200ml.
3) 4 DEG C are placed in overnight, or at least 6 hours.
4) it is centrifuged, 2000g, 30 minutes.
5) liquid is removed, is centrifuged again, 2000g, 5 minutes.
6) residual liquid is carefully absorbed with pipette.
7) the PBS or μ l to 1ml of physiological saline 500 is added.Or add PBS or physiological saline 2.5ml to 5ml.
8) protein concentration is determined, or carries out the Instrumental Analysis such as flow cyctometry.
9) collect and 2000g is centrifuged under the conditions of cells and supernatant, room temperature or 4 DEG C, 10 minutes, remove cell fragment.
10) by culture supernatant or body fluid respectively through a diameter of 1 μm, 0.45 μm and 0.22 μm membrane filtration, to remove it
In apoptotic body that may be present.
Experimental example
A. the stability test of gained cosmetic formulation：
Preserved under the conditions of gained cosmetic formulation is positioned over into -20 DEG C.Observed later at six months, find cosmetic formulation without bright
Aobvious change.
B. validity test：
Eight Mies are selected in beauty parlor, is divided into two groups, one of which tries out gained cosmetic formulation, and another group using conventional
Cosmetics.9 points of the morning of all subjects on the day of experiment is started simultaneously at using corresponding cosmetic formulation, and makees picture, text
Word is recorded.After 12 hours, i.e. at 9 points in evening, unification is observed, log.Assay result is listed in table 1, table 2.
The excretion body of table 1 sustained release cosmetic formulation tries out the result of the test of group
The result of the test of the conventional cosmetic preparations. Control group of table 2
Consolidated statement 1, the result of table 2 it can be found that for the Ms of various types of skins, compared to conventional cosmetic
Preparation, the sustained release cosmetic formulation of human mesenchymal stem cell source excretion body has substantially more lasting cosmetic result, can be effective
Ground solves general cosmetic formulation needs nonexpondable problem in a short time.
Obviously, above-described embodiment is only intended to clearly illustrate example, and not to the restriction of implementation method.It is right
For those of ordinary skill in the art, can also make on the basis of the above description other multi-forms change or
Change.There is no need and unable to be exhaustive to all of implementation method.And the obvious change thus extended out or
Among changing still in the protection domain of the invention.
Claims (10)
1. a kind of preparation method of human umbilical cord mesenchymal stem cells source excretion body biologically active agents, it is characterised in that the system
The preparation method of agent is as follows：
1) shitosan 50-400mg is weighed, is dissolved in the spirit of vinegar of 25-200mL, obtain chitosan solution；
2) human mesenchymal stem cell source excretion body freeze-dried powder 1-10mg, glucose GAG 2-20mg, hyaluronic acid 2- are weighed
20mg, is dissolved in 10-100mL glycerine, obtains excretion liquid solution；
3) described excretion liquid solution is added drop-wise in the chitosan solution, the chitosan nano particle for obtaining excretion body is suspended
Liquid；
4) suspension is carried out into centrifugal treating, collects sediment, be washed out and dried process, obtain the source excretion body
Sustained release cosmetic formulation.
2. preparation as claimed in claim 1, it is characterised in that the shitosan is 200mg, and spirit of vinegar is 100mL, and the human world is filled
Matter stem cell source excretion body freeze-dried powder is 5mg, glucose GAG is 10mg, hyaluronic acid is 10mg, and glycerine is 50mL.
3. preparation as claimed in claim 2, it is characterised in that the adventitia of the excretion body is phophoslipid bilayer structure, it is described outer
Secrete at least one during micro-RNA, mRNA, DNA and nucleic acid of the excretion body source cell are contained in internal portion.
4. preparation as claimed in claim 3, it is characterised in that the acquisition methods step of the excretion body is as follows：
1) human mesenchymal stem cell is cultivated, cultivation stage adds interferon, EPO and PDGF-BB in cell culture medium；
2) stem cell after culture is pre-processed；
3) the MSC excretions body is extracted in the supernatant of culture medium after the pre-treatment.
5. preparation as claimed in claim 4, it is characterised in that the step 1) in, the spirit of vinegar concentration is 0.5%.
6. preparation as claimed in claim 5, it is characterised in that the step 4) in, the speed of the centrifugal treating is
10000r/min, the time is 30 minutes；The step 3) reaction time be 30 minutes；The step 4) in, the washing
Number of times is 3 times.
7. acquisition methods of excretion body as claimed in claim 6, it is characterised in that the specific steps of the pretreatment
For：
1) people's passage MSC is carried out into serum free suspension culture, and it is 1.0 × 10 to adjust cell concentration6/ml；
2) according to 106The big culture dish inoculations of/150mm, culture to cell fusion degree to 70-80%, incubation time is 2-3 days；
3) liquid in culture dish is absorbed, and culture dish is washed with alpha-MEM fluid nutrient medium；
4) alpha-MEM of 20ml is added again in 150mm culture dishes；
5) recombinant human interferon alpha 2, PDGF-BB and EPO are sequentially added；In the MSC nutrient solutions concentration of interferon be 10U/ml~
The concentration of 600U/ml, PDGF-BB is 2ng/ml~60ng/ml, and the concentration of EPO is 0.1IU/ml~5IU/ml.
7) at 37 DEG C, 5% CO2Under the conditions of cultivate 96 hours, collection obtain MSC nutrient solutions.
8. acquisition methods of excretion body as claimed in claim 7, it is characterised in that the step 2) pretreatment it is specific
For：
1) supernatant of the MSC nutrient solutions is taken, centrifugal treating is carried out, cell fragment is removed；
2) and then by the treatment of supernatant membrane filtration, apoptotic body is removed, obtains pretreated supernatant.
9. acquisition methods of excretion body as claimed in claim 8, it is characterised in that the step 3) it is specially：
A) human mesenchymal stem cell is cultivated, cultivation stage adds interferon, EPO and PDGF-BB in cell culture medium；
B) stem cell after culture is pre-processed；
C) the human umbilical cord mesenchymal stem cells source excretion body is extracted in the supernatant of culture medium after the pre-treatment.
10. application of the preparation method in biological beauty preparation preparation field as described in claim any one of 1-9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710262634.8A CN106913583A (en) | 2017-04-20 | 2017-04-20 | The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710262634.8A CN106913583A (en) | 2017-04-20 | 2017-04-20 | The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106913583A true CN106913583A (en) | 2017-07-04 |
Family
ID=59568376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710262634.8A Pending CN106913583A (en) | 2017-04-20 | 2017-04-20 | The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106913583A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475187A (en) * | 2017-09-05 | 2017-12-15 | 山东艾克韦生物技术有限公司 | Nutrient solution and a large amount of production technologies for obtaining umbilical cord mesenchymal stem cells excretion body |
| CN108841787A (en) * | 2018-07-13 | 2018-11-20 | 李璇 | The influence for the excretion body that EPO discharges mescenchymal stem cell |
| CN109172859A (en) * | 2018-09-06 | 2019-01-11 | 上海长海医院 | Human stem cell source excretion bluk recombination exogenous hyaluronic acid is preparing the application in skin wound defect repair drug or material |
| CN109628391A (en) * | 2018-12-30 | 2019-04-16 | 深圳光彩生命工程技术有限公司 | A kind of umbilical cord mesenchymal stem cells excretion body separation method |
| CN109820816A (en) * | 2019-02-18 | 2019-05-31 | 江苏拓弘生物科技有限公司 | Temperature-sensitive biochemical gel preparation and its application |
| CN110123842A (en) * | 2018-02-09 | 2019-08-16 | 上海市第六人民医院 | A kind of excretion body slow-releasing system and its construction method and application |
| CN112553152A (en) * | 2020-10-27 | 2021-03-26 | 重庆市铂而斐细胞生物技术有限公司 | Method for rapidly increasing yield of adipose-derived mesenchymal stem cell exosomes |
| CN116036310A (en) * | 2023-01-13 | 2023-05-02 | 广东医科大学附属医院 | Succinylated chitosan modified exosome and preparation method and application thereof |
| CN116898791A (en) * | 2023-09-14 | 2023-10-20 | 山东博森医学工程技术有限公司 | Medical reagent for whitening skin by utilizing stem cell exosomes |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101636181A (en) * | 2006-12-11 | 2010-01-27 | 莫尔研究应用有限公司 | Novel injectable chitosan mixtures forming hydrogels |
| WO2011010966A1 (en) * | 2009-07-23 | 2011-01-27 | Agency For Science, Technology And Research (A*Star) | Pre-natal mesenchymal stem cells |
| WO2012053976A1 (en) * | 2010-10-18 | 2012-04-26 | Agency For Science, Technology And Research | Use of exosomes to promote or enhance hair growth |
| WO2014054588A1 (en) * | 2012-10-01 | 2014-04-10 | 国立大学法人京都大学 | Nanogel/exosome complex and dds |
| CN103805562A (en) * | 2014-01-13 | 2014-05-21 | 章毅 | Serum-free medium for culturing placenta mesenchymal stem cells |
| WO2015038075A1 (en) * | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method |
| CN104894062A (en) * | 2015-05-19 | 2015-09-09 | 暨南大学 | Stem cell exosome patch and preparation method and application thereof |
| CN105412153A (en) * | 2015-12-10 | 2016-03-23 | 中国人民解放军第二军医大学 | Application of exosome excreted by mesenchymal stem cells for preparing medicine for preventing and treating hepatitis c virus |
| CN105543313A (en) * | 2015-12-29 | 2016-05-04 | 四川新生命干细胞科技股份有限公司 | Human-derived mesenchymal stem cell factor, and preparation method and application thereof |
| CN106282107A (en) * | 2016-08-30 | 2017-01-04 | 章毅 | Human plactnta mescenchymal stem cell source separates outer method and the application thereof secreting body |
| CN106467613A (en) * | 2015-08-19 | 2017-03-01 | 中国科学院大连化学物理研究所 | A kind of self-healing polyanion-chitin quarternary ammonium salt aquagel and its application |
-
2017
- 2017-04-20 CN CN201710262634.8A patent/CN106913583A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101636181A (en) * | 2006-12-11 | 2010-01-27 | 莫尔研究应用有限公司 | Novel injectable chitosan mixtures forming hydrogels |
| WO2011010966A1 (en) * | 2009-07-23 | 2011-01-27 | Agency For Science, Technology And Research (A*Star) | Pre-natal mesenchymal stem cells |
| WO2012053976A1 (en) * | 2010-10-18 | 2012-04-26 | Agency For Science, Technology And Research | Use of exosomes to promote or enhance hair growth |
| WO2014054588A1 (en) * | 2012-10-01 | 2014-04-10 | 国立大学法人京都大学 | Nanogel/exosome complex and dds |
| WO2015038075A1 (en) * | 2013-09-16 | 2015-03-19 | Agency For Science, Technology And Research | Method |
| CN103805562A (en) * | 2014-01-13 | 2014-05-21 | 章毅 | Serum-free medium for culturing placenta mesenchymal stem cells |
| CN104894062A (en) * | 2015-05-19 | 2015-09-09 | 暨南大学 | Stem cell exosome patch and preparation method and application thereof |
| CN106467613A (en) * | 2015-08-19 | 2017-03-01 | 中国科学院大连化学物理研究所 | A kind of self-healing polyanion-chitin quarternary ammonium salt aquagel and its application |
| CN105412153A (en) * | 2015-12-10 | 2016-03-23 | 中国人民解放军第二军医大学 | Application of exosome excreted by mesenchymal stem cells for preparing medicine for preventing and treating hepatitis c virus |
| CN105543313A (en) * | 2015-12-29 | 2016-05-04 | 四川新生命干细胞科技股份有限公司 | Human-derived mesenchymal stem cell factor, and preparation method and application thereof |
| CN106282107A (en) * | 2016-08-30 | 2017-01-04 | 章毅 | Human plactnta mescenchymal stem cell source separates outer method and the application thereof secreting body |
Non-Patent Citations (3)
| Title |
|---|
| HUH MS等: "Polysaccharide-based Nanoparticles for Gene Delivery", 《TOP CURR CHEM (Z)》 * |
| 李毅等: "外泌体中Micro-RNA可作为疾病的生物标志物?", 《中国组织工程研究》 * |
| 杨翔宇等: "干扰素γ刺激hUC-MSCs分泌外泌体促进调节性T细胞生成", 《中国药理学通报》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475187A (en) * | 2017-09-05 | 2017-12-15 | 山东艾克韦生物技术有限公司 | Nutrient solution and a large amount of production technologies for obtaining umbilical cord mesenchymal stem cells excretion body |
| CN110123842A (en) * | 2018-02-09 | 2019-08-16 | 上海市第六人民医院 | A kind of excretion body slow-releasing system and its construction method and application |
| CN110123842B (en) * | 2018-02-09 | 2022-03-15 | 上海市第六人民医院 | Exosome slow-release system and construction method and application thereof |
| CN108841787B (en) * | 2018-07-13 | 2022-08-19 | 上海揽微赛尔生物科技有限公司 | Effect of EPO on exosomes released from mesenchymal Stem cells |
| CN108841787A (en) * | 2018-07-13 | 2018-11-20 | 李璇 | The influence for the excretion body that EPO discharges mescenchymal stem cell |
| CN109172859A (en) * | 2018-09-06 | 2019-01-11 | 上海长海医院 | Human stem cell source excretion bluk recombination exogenous hyaluronic acid is preparing the application in skin wound defect repair drug or material |
| CN109628391A (en) * | 2018-12-30 | 2019-04-16 | 深圳光彩生命工程技术有限公司 | A kind of umbilical cord mesenchymal stem cells excretion body separation method |
| CN109820816A (en) * | 2019-02-18 | 2019-05-31 | 江苏拓弘生物科技有限公司 | Temperature-sensitive biochemical gel preparation and its application |
| CN112553152A (en) * | 2020-10-27 | 2021-03-26 | 重庆市铂而斐细胞生物技术有限公司 | Method for rapidly increasing yield of adipose-derived mesenchymal stem cell exosomes |
| CN116036310A (en) * | 2023-01-13 | 2023-05-02 | 广东医科大学附属医院 | Succinylated chitosan modified exosome and preparation method and application thereof |
| CN116036310B (en) * | 2023-01-13 | 2023-07-04 | 广东医科大学附属医院 | Succinylated chitosan modified exosome and preparation method and application thereof |
| CN116898791A (en) * | 2023-09-14 | 2023-10-20 | 山东博森医学工程技术有限公司 | Medical reagent for whitening skin by utilizing stem cell exosomes |
| CN116898791B (en) * | 2023-09-14 | 2023-12-15 | 山东博森医学工程技术有限公司 | Medical reagent for whitening skin by utilizing stem cell exosomes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106913583A (en) | The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents | |
| CN106109496B (en) | Human umbilical cord mesenchymal stem cells extract freeze-drying powder and preparation method | |
| CN103667187B (en) | A kind of isolated culture method of human adipose-derived stem cell and the construction method of stem cell bank | |
| CN106982821A (en) | Umbilical cord mesenchymal stem cells clinic freezes protection liquid composition and application thereof | |
| CN107080753A (en) | A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body | |
| CN110564682B (en) | Method for large-scale production of human adipose-derived mesenchymal stem cell exosomes | |
| CN102985534A (en) | Culture method for amplifying large numbers of hair follicle stem cells in vitro | |
| KR20050109941A (en) | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | |
| CN110438072A (en) | The preparation method of fat mesenchymal stem cell | |
| CN104622902B (en) | It is a kind of for treating the stem cell medicine of liver fibrosis | |
| US10842820B2 (en) | Kits and methods for processing stem cells from bone marrow or umbilical cord blood | |
| CN107217034A (en) | A kind of human umbilical cord mesenchymal stem cells source excretion body and its acquisition methods and application | |
| CN107006452A (en) | A kind of human umbilical cord mesenchymal stem cells source excretion body freezes store method and its application | |
| CN109453200A (en) | The preparation method of mostly tissue-derived mescenchymal stem cell factor lytic freeze-dried powder | |
| CN107460158A (en) | A kind of inducing umbilical cord mesenchymal stem is divided into the method to form insulin | |
| CN114149965A (en) | Preparation method of ultrapure fresh and live exosome | |
| CN106566803A (en) | Culture solution, application of culture solution and method for culturing umbilical cord mesenchymal stem cells | |
| AU2023206197A1 (en) | Enhanced multipotent cells and microvascular tissue and methods of use thereof | |
| KR100811537B1 (en) | Manufacturing method and it's delivery method of creation and it's remedy of fatty tissue therapeutics | |
| JP6235795B2 (en) | Composition for cell reprogramming | |
| CN107119020A (en) | A kind of hepatic injury targeting mescenchymal stem cell based on miR 9 and preparation method and application | |
| WO2014015229A1 (en) | Isolation of stromal vascular fraction from adipose tissue obtained from postmortem source using ultrasonic cavitation | |
| CN110237026A (en) | A kind of Sodium Hyaluronate compound fat stem cell conditioned medium lyophilized preparation | |
| WO2009116088A2 (en) | A novel composition of stem cells transplantation tolerance | |
| CN109939128A (en) | A kind of neural stem cell preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170704 |